All News

2 June 2009

Merck KGaA at Forefront of Exploring Markers of Response in Continued Effort to Personalize Cancer CareAntibodies

2 June 2009

Inovio Biomedical Influenza DNA Vaccines Demonstrate Potential to Protect Against Newly Emerging Flu Strains with Pandemic PotentialAntibodies

2 June 2009

Investigational Antibody Treatment to Prevent C. difficile Recurrence Highlighted at Digestive Disease Week 2009Antibodies

2 June 2009

New One-Year Data from REMICADE(R) SONIC Trial Show Sustained Efficacy Compared with Azathioprine in Treatment of Crohn’s DiseaseAntibodies

2 June 2009

Xencor Presents Preliminary Phase I Data on XmAb2513 Antibody for Lymphomas at 2009 American Society of Clinical Oncology Annual MeetingAntibodies

2 June 2009

CuraGen Updates CR011-vcMMAE Data at ASCOAntibodies

1 June 2009

Seattle Genetics Reports Data from a Weekly Dosing Phase I Clinical Trial of SGN-35 in LymphomaAntibodies

31 May 2009

Genentech Announces Full Results from First Phase III Study of Avastin in Early-Stage Colon CancerAntibodies

31 May 2009

Novel Targeted Radiation Therapy From Immunomedics Produces Objective Responses in Pancreatic CancerAntibodies

31 May 2009

Antisoma’s AS1409 shows anti-cancer activity in phase I trialAntibodies

31 May 2009

Results from Three Phase 2 Studies Reported a Two-Year Survival Rate Ranging from 30 to 42 Percent in Metastatic Melanoma Patients Treated with Ipilimumab (10 mg/kg)Antibodies

30 May 2009

Immunomedics Reports Updated Results of Milatuzumab in Dose-Escalation Study for Multiple MyelomaAntibodies

30 May 2009

Pfizer Presents Data With Novel Investigational Agents In Select Patient Groups With Non-Small Cell Lung CancerAntibodies

30 May 2009

Pfizer Data Identify Certain Lung Cancer Patients Who May Benefit from Treatment with FigitumumabAntibodies

30 May 2009

ImmunoGen, Inc. Announces Encouraging Trastuzumab-DM1 Phase II Clinical Findings Presented at ASCOAntibodies

29 May 2009

FDA ADVISORY PANEL MAKES FAVORABLE RECOMMENDATION FOR GLAXOSMITHKLINE AND GENMAB’S ARZERRA™ (OFATUMUMAB)Antibodies

29 May 2009

Avastin Plus Commonly Used Chemotherapies Improved Progression-Free Survival in Advanced Breast CancerAntibodies

29 May 2009

Celldex Therapeutics, Inc. Enhances Precision Targeted Immunotherapy Platform with the Acquisition of CuraGen CorporationAntibodies

28 May 2009

Peregrine Pharmaceuticals Reports Progress in Cotara(R) Brain Cancer Clinical ProgramAntibodies

27 May 2009

Medarex Announces Allowance of Investigational New Drug Application for Wholly-Owned Fully Human Anti-CXCR4 Antibody, MDX-1338Antibodies

26 May 2009

FDA Extends Review Timeline for STELARA™ (Ustekinumab) Biologic License Application by Three MonthsAntibodies

25 May 2009

Two-year data reinforce effectiveness of ACTEMRA in inhibiting joint damage and improving physical function in patients with rheumatoid arthritisAntibodies

21 May 2009

Lilly Advances Second Alzheimer’s Disease Treatment Candidate Into Late-Stage Testing by Launching Two Global TrialsAntibodies

21 May 2009

Human Genome Sciences Submits Biologics License Application to FDA for ABthrax(TM)Antibodies

20 May 2009

Genentech and Biogen Idec Submit Applications to the FDA for Rituxan for Most Common Type of Adult LeukemiaAntibodies

18 May 2009

Oxford BioTherapeutics and GlaxoSmithKline Form Strategic Alliance to Develop Novel Cancer Therapeutic AntibodiesAntibodies

15 May 2009

GlobeImmune and Celgene Corporation Announce Strategic Global Oncology AllianceAntibodies

14 May 2009

Sanofi-aventis and Kyowa Hakko Kirin enter into a Collaboration and Licensing Agreement on an Anti LIGHT fully human monoclonal antibodyAntibodies

14 May 2009

Medarex Announces Primary Endpoint Achieved in MDX-1100 Anti-IP-10 Antibody Phase 2 Trial for Rheumatoid ArthritisAntibodies

14 May 2009

UCB’s CIMZIA® (certolizumab pegol) approved by the U.S. FDA for adult patients suffering from moderate to severe rheumatoid arthritisAntibodies

News Channels

Newsletter

La Merie Biologics

La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.

Newsletter La Merie Biologics

Newsletter

New Product Alert

La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.

Newsletter new product alert

Featured reports

FcRn Inhibitors Pipeline Review

TL1A Inhibitor Pipeline Review

PD-L1 x 4-1BB (CD137) Bispecific Antibody Pipeline Review

Bispecific Antibodies for Immuno-Oncology & Other Diseases

PSMA-Targeted Therapy Pipeline Review

Biologics Sales Database for Antibodies, Proteins, Biosimilars, Gene & Cell Therapy and RNA

Ustekinumab (Stelara) Biosimilars Pipeline Review

Targeted Protein Degradation by Novel PROTACs and Molecular Glues 2020: a landscape analysis of companies, technologies, targets, investors and partners from an industry perspective

Blockbuster Biologics 2019: Sales of Recombinant Therapeutic Antibodies & Proteins

Blockbuster Biologics 2018: Sales of Recombinant Therapeutic Antibodies & Proteins